Genetic Predictors of AML Treatment Response
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,500
- 试验地点
- 1
- 主要终点
- Incidence of first acute myeloid leukemia relapse
研究概览
简要总结
This research trial studies deoxyribonucleic acid (DNA) in blood or bone marrow samples from younger patients with acute myeloid leukemia. Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
详细描述
PRIMARY OBJECTIVES:
l. Perform a genome-wide scan to test for loci associated with acute myeloid leukemia (AML) relapse and infection risk.
II. Validate positive associations seen in the genome-wide scan with a fine mapping approach.
III. Perform simulated clinical trials using germline genetic variation data to test the feasibility of using genetic data to inform the clinical care of pediatric patients with AML.
OUTLINE:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- — 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of AML
- •In remission
- •Adequate DNA from peripheral blood or bone marrow samples
- •Concurrent enrollment on CCG-2961, COG-AAML03P1, COG-AAML0531, AML-93, AML-97, AML-04,AML-09, or Canada AML Infection clinical trial required
排除标准
- 未提供
结局指标
主要结局
Incidence of first acute myeloid leukemia relapse
时间窗: Up to 2 years
Rate of invasive bacterial infections defined as the number of invasive infection episodes divided by the days at risk
时间窗: From study entry date to completion of therapy date provided on the final Reporting Period case reporting form, assessed up to 2 years
次要结局
未报告次要终点